Figitumumab

Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM[1].

Product Specifications

CAS Number

[943453-46-1]

Product Name Alternative

CP-751871

UNSPSC

12352203

Target

IGF-1R

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/figitumumab.html

Purity

99.80

Solubility

10 mM in DMSO

Smiles

[Figitumumab]

Molecular Weight

(144.5 kDa)

References & Citations

[1]Pavlicek A, et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871) . Mol Cancer Ther. 2013 Dec;12 (12) :2929-39.|[2]Cohen BD, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005 Mar 1;11 (5) :2063-73.